Positive News SentimentPositive NewsNASDAQ:RPTX Repare Therapeutics (RPTX) Stock Price, News & Analysis $3.94 +0.04 (+1.03%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.89▼$4.0150-Day Range$3.10▼$4.0252-Week Range$2.98▼$13.85Volume97,843 shsAverage Volume193,186 shsMarket Capitalization$167.21 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Repare Therapeutics alerts: Email Address Repare Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside339.9% Upside$17.33 Price TargetShort InterestHealthy3.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.35) to ($3.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.23 out of 5 starsMedical Sector359th out of 936 stocksPharmaceutical Preparations Industry167th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingRepare Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRepare Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Repare Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.11% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Repare Therapeutics has recently increased by 4.02%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRepare Therapeutics does not currently pay a dividend.Dividend GrowthRepare Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPTX. Previous Next 3.3 News and Social Media Coverage News SentimentRepare Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Repare Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for RPTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repare Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repare Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.35) to ($3.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repare Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repare Therapeutics is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRepare Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Repare Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Monument Traders AllianceNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands of Americans...Click here to see how >>> About Repare Therapeutics Stock (NASDAQ:RPTX)Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Read More RPTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPTX Stock News HeadlinesJune 26, 2024 | businesswire.comRepare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRIJune 12, 2024 | businesswire.comFoundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for LunresertibJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."June 10, 2024 | businesswire.comRepare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialMay 29, 2024 | businesswire.comRepare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024May 19, 2024 | finance.yahoo.comRepare Therapeutics Inc. (RPTX)May 12, 2024 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX)May 11, 2024 | morningstar.comRepare Therapeutics Inc Ordinary SharesJuly 27, 2024 | Behind the Markets (Ad)J.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."May 9, 2024 | finance.yahoo.comRepare Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | finanznachrichten.deRepare Therapeutics Inc.: Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | marketwatch.comRepare Therapeutics Shares Rise 17% After 1Q Earnings, Revenue BeatsMay 8, 2024 | theglobeandmail.comSmall Cap Massively Bid Following Key Q1 Earnings BeatMay 7, 2024 | businesswire.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsApril 30, 2024 | businesswire.comDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 InhibitionApril 30, 2024 | businesswire.comRepare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 InhibitionApril 28, 2024 | investing.comRepare Therapeutics appoints new board memberApril 26, 2024 | finance.yahoo.comRepare Therapeutics Appoints Steven H. Stein, M.D. to its Board of DirectorsSee More Headlines Receive RPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RPTX CUSIPN/A CIK1808158 Webwww.reparerx.com Phone857-412-7018FaxN/AEmployees180Year Founded2016Price Target and Rating Average Stock Price Target$17.33 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+339.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,800,000.00 Net Margins-46.69% Pretax Margin-59.33% Return on Equity-19.81% Return on Assets-16.54% Debt Debt-to-Equity RatioN/A Current Ratio8.33 Quick Ratio8.33 Sales & Book Value Annual Sales$51.13 million Price / Sales3.27 Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book0.78Miscellaneous Outstanding Shares42,440,000Free Float33,277,000Market Cap$167.21 million OptionableOptionable Beta0.73 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Lloyd Mitchell Segal (Age 60)President, CEO & Director Comp: $932.18kMr. Steve Forte (Age 45)Executive VP & CFO Comp: $632kDr. Maria Koehler M.D. (Age 67)Ph.D., Executive VP & Chief Medical Officer Comp: $693.28kDr. Daniel Durocher Ph.D.Co-FounderDr. Frank Sicheri Ph.D.Co-FounderDr. Agnel Sfeir Ph.D.Co-FounderDr. Michael Zinda Ph.D. (Age 53)Executive VP & Chief Scientific Officer Comp: $641.53kMr. Daniel BelangerExecutive Vice President of Human ResourceMr. Cameron BlackExecutive Vice President of DiscoveryDr. Kim A. Seth Ph.D.Executive VP & Chief Business OfficerMore ExecutivesKey CompetitorsBlack Diamond TherapeuticsNASDAQ:BDTXMineralys TherapeuticsNASDAQ:MLYSSavaraNASDAQ:SVRAAcelyrinNASDAQ:SLRNArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsARK Investment Management LLCSold 73,419 shares on 7/26/2024Ownership: 6.198%Sumitomo Mitsui Trust Holdings Inc.Sold 31,281 shares on 7/19/2024Ownership: 0.653%Opaleye Management Inc.Bought 67,561 shares on 5/29/2024Ownership: 0.159%Redmile Group LLCSold 132,446 shares on 5/16/2024Ownership: 4.751%Acadian Asset Management LLCBought 46,648 shares on 5/10/2024Ownership: 0.315%View All Insider TransactionsView All Institutional Transactions RPTX Stock Analysis - Frequently Asked Questions How have RPTX shares performed this year? Repare Therapeutics' stock was trading at $7.30 on January 1st, 2024. Since then, RPTX stock has decreased by 46.0% and is now trading at $3.94. View the best growth stocks for 2024 here. How were Repare Therapeutics' earnings last quarter? Repare Therapeutics Inc. (NASDAQ:RPTX) issued its quarterly earnings data on Tuesday, May, 7th. The company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.40. The business earned $52.40 million during the quarter, compared to the consensus estimate of $34.82 million. Repare Therapeutics had a negative net margin of 46.69% and a negative trailing twelve-month return on equity of 19.81%. When did Repare Therapeutics IPO? Repare Therapeutics (RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler served as the underwriters for the IPO. Who are Repare Therapeutics' major shareholders? Repare Therapeutics' top institutional shareholders include ARK Investment Management LLC (6.20%) and Sumitomo Mitsui Trust Holdings Inc. (0.65%). Insiders that own company stock include Bvf Partners L P/Il, Lloyd Mitchell Segal, Michael Zinda, Steve Forte, Orbimed Advisors Llc, Thomas Civik and David P Bonita. View institutional ownership trends. How do I buy shares of Repare Therapeutics? Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Repare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT) and This page (NASDAQ:RPTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repare Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
